<?xml version="1.0" encoding="UTF-8"?>
<p>For platelets, according to the 2018 update of the iwCLL guidelines, a count &lt;100 × 10
 <sup>9</sup>/l does not require immediate therapeutic intervention and can be tolerated, according to the bleeding risk, with regular monitoring.
 <sup>
  <xref rid="R34" ref-type="bibr">34</xref>
 </sup> One should also remember that thrombocytopenia may be a feature of the initial presentation of COVID-19.
 <sup>
  <xref rid="R72" ref-type="bibr">72</xref>–
  <xref rid="R74" ref-type="bibr">74</xref>
 </sup> Immune thrombocytopenia can be effectively treated with corticosteroids but also with agents that are not immunosuppressive, such as intravenous immunoglobulin and oral thrombopoietic (TPO) agents.
 <sup>
  <xref rid="R75" ref-type="bibr">75</xref>
 </sup> Up to 78% of patients with CLL and immune thrombocytopenia respond to eltrombopag.
 <sup>
  <xref rid="R76" ref-type="bibr">76</xref>
 </sup> Potential increased risk of thrombosis, which is also a concern in COVID-19,
 <sup>
  <xref rid="R77" ref-type="bibr">77</xref>
 </sup> has been reported with the use of TPO agents and should be taken into account.
 <sup>
  <xref rid="R75" ref-type="bibr">75</xref>
 </sup> While prophylactic anticoagulation is recommended for hospitalized COVID-19 patients, its use in the outpatient setting for COVID-19 thrombosis prevention is not supported by prospective clinical trial data.
</p>
